Investor Relations


Common Stock

Data as of

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Company Overview

Are you eager to deep-dive into Evaxion's business? Download our company presentation, or click here to see all our latest presentations.

Latest News

Press Release

Jul 16, 2024

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and proprietary data, Evaxion has

Press Release

Jul 03, 2024

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders.

Press Release

June 26, 2024

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all relevant claims in

Press Release

Jun 17, 2024

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s personalized cancer vaccine, EVX-01, in patients with metastatic melanoma The findings also demonstrate strong and clinically relevant immune responses after EVX-01


Subscribe to Investor Email Alerts

Be the first to know about news, milestones and events at Evaxion by subscribing to our investor email alerts.